fbpx Yourgene Health plc - Home
004-news.jpg
002-news.jpg
003-news.jpg
001-news.jpg
DSC00185r.jpg
previous arrow
next arrow

Since the beginning of the global COVID-19 outbreak, the diagnostic and research community has undertaken an unprecedented effort to understand how best to manage, eradicate and prevent the disease. Two key pillars in the fight against the pandemic are establishing a robust testing strategy and implementing procedures and processes to reduce the burden on healthcare systems.  

Independent SAGE recently published a document containing core recommendations for how best to optimize and develop the current testing environment (1). It is clear that a wider reaching, more efficient testing strategy is desperately needed - in the UK Baroness Harding (head of NHS Test and Trace) recently briefed the science and technology committee that the number of individuals looking to book a test was three to four times the capacity of the service (2). Outside of the centralised testing systems employed by most Governments across the world, many businesses keen to bring staff back into the workplace have turned to private health companies to meet demand. Other sectors, including universities and independent schools, have also contributed to demand for private testing being thirty times higher than that seen in the summer (3). Facilities have responded in kind, with some creating ‘pop up’ facilities to facilitate the collecting and processing of extra samples (3). Manufacturers of testing kits have also responded by focusing efforts on maximising the ease and efficiency of testing. One area of innovation has been optimising saliva testing in order to move away from the need for nasopharyngeal swabs, which is labour intensive and usually requires close contact with a healthcare professional. 

Despite the collective effort of both the public and private healthcare sectors to increase capacity and develop the testing pathway, diagnosing and identifying cases remains only one of the pillars needed to protect communities and manage the pandemic.

At the onset of the pandemic countries across the world put in place national initiatives to increase the number of available hospital beds and associated staffing resource. Leishenshan Hospital in Wuhan was one of the hospitals built by China in order to handle the large number of COVID-19 patients. The hospital was built in a record time of just 2 weeks, whilst in the UK 7 critical care hospitals were opened in the space of just over a month. 

Alongside such efforts to expand capacity, healthcare systems have worked to reduce the burden on resources – in particular the demand for intensive care unit (ICU) beds. In many countries the public were asked to stay at home except where absolutely necessary, such as to buy food or care for a vulnerable family member. This not only reduced the spread of COVID-19, but also reduced the number of accidents that are associated with travel. In the Tarragona province of Spain the number of traffic accidents fell by almost 75% (4). Difficult decisions were made around prioritising ICU beds and treatment for those critically ill patients who were most likely to benefit from such intervention (5). However, arguably the intervention with the largest impact was many hospitals making the decision to downscale all out-patient clinics and non-urgent interventions and surgeries. Policies were clear, however, that all cancer treatments and other clinically urgent care should continue unaffected (6). 

This raises the question as to whether there are available strategies that could be implemented to reduce the need for intensive care escalation among patients undergoing cancer treatments or other urgent interventions. Fluorouracil (5-FU) and Capecitabine, a prodrug of 5-FU, are fluoropyrimidine chemotherapy agents used in the treatment of cancer. These drugs form a key component of the chemotherapy regime for colorectal, breast, heapato-pancreato-biliary and many other cancers. These drugs are catabolised by the dihydropyrimadine deyhydrogenase (DPD) enzyme, itself encoded by the DPYD gene. Approximately 3–5% of the European population have a partial DPD enzyme deficiency due to a mutation in the gene (7), and complete enzyme deficiency has also been described. In the US it is reported that up to 8% of the general population have at least a partial deficiency (8). Individuals with a complete deficiency are at risk of life threatening or even fatal chemotherapy toxicity when given 5-FU or Capecitabine. Those with a partial deficiency usually experience gastrointestinal adverse reactions such as prolonged vomiting, as well as haematological effects including a decreased white blood cell count when given therapy at the standard dose. The latter puts patients at risk of serious infection, and a fever is often also reported in those with a partial deficiency. Some studies have shown that almost 25% of patients who are given fluoropyrimidine chemotherapy as a first-line drug experience severe toxicity (9). DPYD testing allows for those with a partial or complete deficiency to be identified, and either a modified dose or alternative therapy given to prevent such adverse reactions. In addition to the clear clinical benefit for the patient, a recent study reported that the average cost of an ICU admission following DPYD toxicity was almost €47,000 per person, and as such that pre-emptive DPYD screening of all patients is a cost-effective strategy (9). Many countries are beginning to recognise the clinical and economic benefit of universal pre-emptive DPYD genotyping. Wales is the first nation in the UK to offer the DPYD test to all patients, with over 400 samples already taken and 6% of patients returning a positive result. All Wales Medical Genomics Service (AWMGS) commenced a pilot phase earlier this year using the Elucigene DPYD assay, which then led to the launch of the nation-wide service (10). Similarly the German Federal Joint Committee, G-BA, the national reimbursement authority in Germany, recently approved reimbursement for DPYD testing across the country. Many countries could benefit from adopting similar approaches, especially in the current climate of extra pressure on ICU resources. 

It is clear that testing has a key role to play in managing a successful response to the COVID-19 pandemic. Alongside continuing to support initiatives that foster a robust viral testing and tracing programme, Governments across the world should look to examples of where other testing, such as DPYD screening, is being used innovatively to reduce the burden on resources of critical importance during the pandemic. 

Click here to find out how Yourgene Health can support your organisation in delivering COVID testing. You can also find out how about our range of genotyping tests, including our CE-marked DPYD assay.

1. Independent SAGE: The complexities of testing for COVID-19: the why, the who and the how https://www.independentsage.org/wp-content/uploads/2020/09/Indie-SAGE-testing-document-Final-110920-12.05.pdf

2. Coronavirus: Test demand 'significantly outstripping' capacity https://www.bbc.co.uk/news/uk-54194302

3. Private groups race to meet Covid testing demand from UK companies https://www.ft.com/content/17c5a06e-7987-415f-ad60-78102535a12f

4. COVID-19 lockdown and reduction of traffic accidents in Tarragona province, Spain https://www.sciencedirect.com/science/article/pii/S2590198220301299

5. Prioritisation of ICU treatments for critically ill patients in a COVID-19 pandemic with scarce resources https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230138/

6. Covid-19: all non-urgent elective surgery is suspended for at least three months in England https://www.bmj.com/content/368/bmj.m1106

7. DPYD Testing – Manchester University https://mft.nhs.uk/dpyd/

8. Dihydropyrimidine dehydrogenase deficiency https://rarediseases.info.nih.gov/diseases/19/dihydropyrimidine-dehydrogenase-deficiency

9. Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168732/

10. Elucigene DPYD tests to be used routinely in Wales https://www.yourgene-health.com/about/press-releases/20-news/1702-12-october-2020-elucigene-dpyd-tests-to-be-used-routinely-in-wales

  • Ranger® Revolution - LightBench® Detect is here! - 20 June 2022 +

    Ranger® Revolution - LightBench® Detect is Here!

    The wait is over! Yourgene Health are proud to today reveal the Ranger® Revolution in the form of the LightBench® Detect; the latest addition to our Ranger® Technology portfolio. We’ve worked closely with our clinical laboratory partners to develop a size selection instrument that is optimised for improving the performance of liquid biopsy workflows, most notably non-invasive prenatal testing (NIPT). The LightBench® Detect addresses a pressing need for NIPT

    Read More
  • Collaboration to Perform: Yourgene Microdeletions Plugin Accelerator - 24 May 2022 +

    Yourgene Health is today unveiling the Yourgene Microdeletions Plugin Accelerator phase, following a successful pilot project with LifeStrands Genomics. This Accelerator represents a new era in Yourgene’s approach to delivery of NIPT testing solutions, with a focus on ‘Collaboration to Perform’. Working as a partnership, rather than the traditional laboratory/manufacturer relationship, represents a shared commitment to ensuring high-quality and performance-driven testing, ultimately delivering better outcomes for patients.

    The Plugin has been designed for use with

    Read More
  • Exclusion criteria for NIPT explained - 15 February 2022 +

    The IONA ® test is a non-invasive prenatal test (NIPT) for pregnant women which estimates the risk of a fetus having Down’s syndrome (Trisomy 21), Edwards’ syndrome (Trisomy 18) and Patau’s syndrome (Trisomy 13). The test is performed by analysing cell-free placental-fetal DNA from a maternal blood sample. The test is suitable for women who are at least 10 weeks pregnant, prior to ten weeks there is a risk that there would be insufficient placental-fetal cell

    Read More
  • International Women and Girls in Science Day 2022 +

    Here at Yourgene Health, we are very proud that a large proportion of our genomic technologies and services business, including senior leadership and laboratory managers, are powerful women. We believe it is important to showcase the impressive range of talent we are lucky to have, including our women and girls in science.

    In light of the International Day of Women and Girls in Science, we would like to place a spotlight on a few members

    Read More
  • New Year, New Regulations - 19 January 2022 +

    The ‘New Year's resolution’ is a tradition almost all of us are familiar with, in which a person resolves to accomplish a personal goal, continue good habits or change undesirable ones all with the intention of self-improvement. A study of over 800 million activity data points on the exercise platform Strava found that today, January 19th, is the most common day for a New Year’s resolution to be abandoned ( 1 ). If you are reading this

    Read More
  • Behind the scenes: Adapting diagnostic services during a pandemic - 11 November 2021 +

    The diagnostic testing business has always been dynamic and opportunistic , but nothing could have stretched the definition of these 2 words like a pandemic.

    Since the launch of Yourgene Genomic Services 6 months into this global pandemic – born from a legacy, well established NIPT service laboratory, a modest acquisition, and an unprecedented national genomic testing demand, we have vastly expanded our testing capacity by converting every spare inch of underutilised office space created by remote

    Read More
  • Overprescribing within the NHS - 02 November 2021 +

    “Good for you, good for us but is it good for everybody?”
    Overprescribing within the NHS – October 2021


    The NHS is currently the 5th largest global employer; with over 1.3m employees and receiving around 10% of the UK Government’s annual spending. It is estimated that the NHS deals with 336 million ‘patient visits’ per year, - many of whom will receive some form of at least one ‘prescription’ per visit and at a current charge in

    Read More
  • The role genomics plays in relationships - 18 August 2021 +

    According to National Today, the website dedicated to highlighting every day celebrations and holidays, August 18 th is ‘National Couple’s Day’ – a day to celebrate the important relationships in life. Whilst not an official holiday or observance in any country, the clinical team at Yourgene Health wanted to use this opportunity to reflect upon the pivotal role that genomics plays in relationships across the world.

    Earlier this year a study, published in Nature Human Behaviour,

    Read More
  • NIPT for Sex Chromosome Aneuploidies and Autosomal Aneuploidies. A Q&A with Dr Greg Fitzgibbon - 26 May 2021 +

    Yourgene Health has recently launched IONA ® Care , an advanced prenatal screening test that performs whole-genome analysis to measure the likelihood that a pregnant woman is carrying a fetus with one the most common trisomies (trisomy 21, 18 and 13), any other Autosomal Aneuploidy (AA) or a Sex Chromosome Aneuploidy (SCA). IONA ® Care is available from the Yourgene Genomic Services laboratory in Manchester, UK. The test is available as a menu, enabling pregnant women, their families

    Read More
  • COVID-19 testing and the need for regulation - 6 May 2021 +

    The COVID-19 pandemic presented huge challenges worldwide. In response to the unprecedented need for COVID-19 PCR testing, the UK government set up a new network of Lighthouse laboratories across the country to provide the required capacity for testing thousands of samples each day. These laboratories proved a vital part of the test and trace strategy but were also under immense pressure to meet their targets and, following an investigation by Panorama , it was found that

    Read More
  • Yourgene on World Creativity and Innovation Day 2021 - 21 April 2021 +

    Innovation and creativity are two pillars at the heart of technological and scientific advances. The instrumental role they play has been recognised by the United Nations (UNN), who have designated a special day to raise awareness of the importance of innovation in culture and economic growth worldwide: 21st April. World Creativity and Innovation Day (UNN) is a day to encourage people to “think outside the box”, find new perspectives which push personal growth, identify different

    Read More
  • The IONA® test recommended for twin pregnancies screening for Down’s syndrome - 7 April 2021 +

    In recent years, fertility treatments and the fact women are having babies later has made multiple births more common. In 2016, around 12,000 sets of twins and about 190 sets of triplets or more were born in the UK. That means about 1 in every 65 births in the UK today are twins, triplets or more. 1 Extensive studies have been carried out for cell-free DNA (cfDNA) testing in singleton pregnancies with sample numbers into

    Read More
  • Blood clots, inherited thrombophilia and COVID-19 - 25 March 2021 +

    Recent reports in the media from a collection of European countries suggest that there may be cause for concern with regards to the Oxford AstraZeneca COVID-19 vaccine and abnormal blood clotting. According to Norway’s medicines agency (NoMA), four new cases of “serious blood clotting in adults” have been identified following a recent review (1). Austria have suspended the use of one particular batch of the vaccine after two events, including an individual diagnosed with multiple

    Read More
  • COVID-19 strains - what are they and why do they matter? A Q&A with Dr Michael Risley - 28 January 2021 +

    The COVID-19 pandemic, also known as the coronavirus pandemic, is an ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the beginning of the global COVID-19 outbreak, the diagnostic and research community has undertaken an unprecedented effort to understand how best to manage, eradicate and prevent the disease. In recent months we have seen the rollout of ambitious vaccination schedules worldwide, as well as the strengthening of

    Read More
  • So much to be proud of! - 23 December 2020 +

    As many have already said and written, this year has been like none other. This has been especially true for conferences and exhibitions. Every year, the commercial team at Yourgene look forward to exhibiting at various conferences globally. It’s a chance to meet our partners and customers, as well as form new relationships. With the COVID-19 pandemic none of this was possible, so when we heard that the Taiwan Healthcare Expo was still going ahead,

    Read More
  • 1
  • 2